STOCK TITAN

TVTX (NASDAQ: TVTX) holder plans 7,242-share sale after RSU vest

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Christopher Cline filed notice of a planned sale of 7,242 shares of common stock of TVTX, with an aggregate market value of $232,616.03. The shares are to be sold on February 3, 2026 on the NASDAQ through Morgan Stanley Smith Barney.

The 7,242 shares were acquired on January 31, 2026 through restricted stock unit vesting from the issuer as compensation. Over the prior three months, Cline sold 20,000 common shares on December 1, 2025, generating $700,202.00 in gross proceeds.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for TVTX disclose?

The Form 144 filing discloses that Christopher Cline plans to sell 7,242 TVTX common shares. These shares, valued at $232,616.03, will be sold on NASDAQ through Morgan Stanley Smith Barney, following their acquisition via restricted stock unit vesting on January 31, 2026.

How many TVTX shares is Christopher Cline planning to sell under this notice?

Christopher Cline plans to sell 7,242 TVTX common shares. The filing lists an aggregate market value of $232,616.03 for these shares, to be sold on NASDAQ on or about February 3, 2026, using Morgan Stanley Smith Barney as the broker.

How did Christopher Cline acquire the 7,242 TVTX shares being sold?

The 7,242 TVTX shares come from restricted stock units that vested on January 31, 2026. The filing states the shares were acquired from the issuer as compensation, with the payment date matching the vesting date, indicating they were granted as part of an equity award.

What prior TVTX share sales by Christopher Cline are disclosed?

The filing reports that Christopher Cline sold 20,000 TVTX common shares on December 1, 2025. These sales generated gross proceeds of $700,202.00, and are disclosed as securities sold during the past three months for aggregation under Rule 144 requirements.

Which broker and exchange are involved in the planned TVTX share sale?

The planned sale will be executed through Morgan Stanley Smith Barney, located in Alpharetta, Georgia. The Form 144 indicates that the 7,242 TVTX common shares are expected to be sold on the NASDAQ exchange on or about February 3, 2026.

What representation does the seller make in the TVTX Form 144 notice?

By signing the notice, the seller represents that they do not know any material adverse, nonpublic information about TVTX. The representation also applies as of any Rule 10b5-1 trading plan adoption date, if such a plan or trading instructions have been used.
Travere Therapeutics Inc

NASDAQ:TVTX

TVTX Rankings

TVTX Latest News

TVTX Latest SEC Filings

TVTX Stock Data

2.96B
82.79M
0.75%
117.25%
13.55%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO